Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 84


The role of drug susceptibility testing in M/XDR-TB. Too little and too late - Are we doing the right things?

Hoffner SE.

Int J Mycobacteriol. 2013 Dec;2(4):191-3. doi: 10.1016/j.ijmyco.2013.10.003. No abstract available.


The need for improved tuberculosis control.

Hoffner SE, Jonsson J.

Lancet Infect Dis. 2013 Sep;13(9):731-2. doi: 10.1016/S1473-3099(13)70150-6. No abstract available.


Differential cellular recognition pattern to M. tuberculosis targets defined by IFN-γ and IL-17 production in blood from TB + patients from Honduras as compared to health care workers: TB and immune responses in patients from Honduras.

Alvarez-Corrales N, Ahmed RK, Rodriguez CA, Balaji KN, Rivera R, Sompallae R, Vudattu NK, Hoffner SE, Zumla A, Pineda-Garcia L, Maeurer M.

BMC Infect Dis. 2013 Mar 6;13:125. doi: 10.1186/1471-2334-13-125.


Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.

Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T.

Bull World Health Organ. 2012 Sep 1;90(9):693-8. doi: 10.2471/BLT.11.096644.


Drug resistance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions.

Rosales-Klintz S, Jureen P, Zalutskayae A, Skrahina A, Xu B, Hu Y, Pineda-Garcia L, Merza MA, Muntean I, Bwanga F, Joloba M, Hoffner SE.

Int J Mycobacteriol. 2012 Sep;1(3):124-30. doi: 10.1016/j.ijmyco.2012.08.001.


Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing.

Engström A, Morcillo N, Imperiale B, Hoffner SE, Juréen P.

J Clin Microbiol. 2012 Jun;50(6):2026-33. doi: 10.1128/JCM.06664-11.


Pattern recognition and cellular immune responses to novel Mycobacterium tuberculosis-antigens in individuals from Belarus.

Ahmed RK, Rohava Z, Balaji KN, Hoffner SE, Gaines H, Magalhaes I, Zumla A, Skrahina A, Maeurer MJ.

BMC Infect Dis. 2012 Feb 15;12:41. doi: 10.1186/1471-2334-12-41.


Microevolution of extensively drug-resistant tuberculosis in Russia.

Casali N, Nikolayevskyy V, Balabanova Y, Ignatyeva O, Kontsevaya I, Harris SR, Bentley SD, Parkhill J, Nejentsev S, Hoffner SE, Horstmann RD, Brown T, Drobniewski F.

Genome Res. 2012 Apr;22(4):735-45. doi: 10.1101/gr.128678.111.


Field assessment of the direct nitrate reductase assay for rapid detection of multidrug-resistant tuberculosis in Honduras.

Rosales S, Almendarez N, Membreño H, Hoffner SE, Pineda-Garcia L.

Int J Tuberc Lung Dis. 2011 Sep;15(9):1206-10, i. doi: 10.5588/ijtld.10.0697.


Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.

Engström A, Perskvist N, Werngren J, Hoffner SE, Juréen P.

J Antimicrob Chemother. 2011 Jun;66(6):1247-54. doi: 10.1093/jac/dkr109.


Molecular diversity of Mycobacterium tuberculosis isolates from patients with tuberculosis in Honduras.

Rosales S, Pineda-García L, Ghebremichael S, Rastogi N, Hoffner SE.

BMC Microbiol. 2010 Aug 3;10:208. doi: 10.1186/1471-2180-10-208.


Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.

Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T.

J Antimicrob Chemother. 2010 May;65(5):946-52. doi: 10.1093/jac/dkq091.


Ad fontes!

Hoffner SE, Salfinger M.

Int J Tuberc Lung Dis. 2010 Mar;14(3):260. No abstract available.


Evaluation of the nitrate reductase assay for rapid detection of extensively drug-resistant tuberculosis.

Rosales S, Pineda-García L, Andino N, Almendarez N, Membreño H, Hoffner SE.

Int J Tuberc Lung Dis. 2009 Dec;13(12):1542-9.


Results of the external quality assessment of Mycobacterium tuberculosis drug susceptibility testing in Russia, 2005-2007.

Shulgina MV, Malakhov VN, Hoffner SE, Haile M, Wright A.

Int J Tuberc Lung Dis. 2009 Oct;13(10):1294-300.


Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.

Schön T, Juréen P, Giske CG, Chryssanthou E, Sturegård E, Werngren J, Kahlmeter G, Hoffner SE, Angeby KA.

J Antimicrob Chemother. 2009 Oct;64(4):786-93. doi: 10.1093/jac/dkp262.


Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.

Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, Hoffner SE.

Chest. 2009 Aug;136(2):420-5. doi: 10.1378/chest.08-2427.


In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor.

Huitric E, Verhasselt P, Andries K, Hoffner SE.

Antimicrob Agents Chemother. 2007 Nov;51(11):4202-4.


Rapid detection of rifampin resistance in Mycobacterium tuberculosis by Pyrosequencing technology.

Jureen P, Engstrand L, Eriksson S, Alderborn A, Krabbe M, Hoffner SE.

J Clin Microbiol. 2006 Jun;44(6):1925-9.

Items per page

Supplemental Content

Loading ...
Support Center